Dual Treatment of Chronic Pain and Insomnia

Sponsor
Mary Free Bed Rehabilitation Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05033418
Collaborator
(none)
114
1
2
22.7
5

Study Details

Study Description

Brief Summary

This study is to evaluate a group-based cognitive behavioral therapy for insomnia (CBT-I) intervention delivered in an interdisciplinary pain rehabilitation program (IPRP) compared to usual care.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I)
  • Behavioral: Interdisciplinary Pain Rehabilitation Program (IPRP)
N/A

Detailed Description

Dual Treatment of Chronic Pain and Insomnia within an Interdisciplinary Pain Rehabilitation Program

The aim of this project is to develop a dual treatment model for chronic pain and insomnia by combining evidence-based approaches for each condition, addressing an important gap in the research on and treatment of chronic pain.

Insomnia is frequently comorbid among patients with chronic pain. Estimates suggest that 50-80% of patients receiving treatment for chronic pain also report significant insomnia. Patients with comorbid insomnia and chronic pain are at higher risk of negative outcomes compared to individuals without insomnia. More specifically, studies have found that higher levels of insomnia are associated with increased difficulty in reducing opioid use, higher pain intensity, greater functional limitations, lower self-efficacy, higher pain catastrophizing, and more depressive symptoms compared to patients with less severe insomnia. Importantly, for patients with clinically significant insomnia symptoms, insomnia often does not improve to a meaningful extent as a result of chronic pain treatment alone. Accordingly, there is a significant need for dual treatment models that address both chronic pain and insomnia.

Cognitive-Behavioral Therapy for Insomnia (CBT-I) CBT-I is viewed as the "gold standard" treatment for clinical insomnia. In this treatment model, insomnia is viewed as originating from varying precipitating events (e.g., illness, life changes, pain symptoms), but maintained through sleep-related behaviors that increase sleep-related arousal, fragment sleep, and condition an association between bed/nighttime and wakefulness. Accordingly, CBT-I uses conditioning principles to decrease pre-sleep arousal and recondition a pattern of rapid, consolidated sleep. The key components of this intervention are sleep restriction therapy (SRT), which limits time in bed initially to the duration of actual sleep per night, and stimulus control (SC), which involves modification of factors that associate bed/nighttime with wakefulness (e.g., time awake in bed, wakeful activities in bed).

Several randomized controlled trials (RCTs) have been conducted to evaluate this treatment among patients with insomnia and a variety of comorbid chronic pain conditions.8 When compared to usual care or a waiting list control group, patients assigned to receive CBT-I have reported significantly better improvements in insomnia symptoms. In addition, results indicate that the effects of CBT-I delivered to patients with chronic pain have been maintained or improved over time.

Interdisciplinary Pain Rehabilitation and Outcomes for Chronic Pain and Insomnia Interdisciplinary pain rehabilitation programs (IPRPs) are evidence-based treatments for chronic pain. These programs emphasize functional restoration and typically involve physical and occupational therapy, medical visits, and mental health visits. Although these programs typically include sleep hygiene training, research indicates that while patients experience significant gains in improving pain, functioning, and quality of life, IPRPs alone are insufficient for improving clinical insomnia. Hybrid interventions for pain and insomnia have demonstrated successful outcomes for treating sleep disturbance and chronic pain. However, the incorporation of CBT-I into and IPRP has not been previously studied. This gap in research has been previously documented and represents an important area for future study.

The Current Study The current study aims to assess the effectiveness of CBT-I within the context of a 10-week outpatient IPRP and evaluate whether participation leads to superior outcomes compared to pain rehabilitation alone.

Hypothesis 1: Insomnia severity will be associated with pain-related outcomes among patients presenting for chronic pain treatment.

Hypothesis 2: CBT-I participation will be associated with significant improvement in insomnia symptoms.

Hypothesis 3: Compared to a waitlist control group, patients who participate in CBT-I will have superior treatment outcomes from a pain rehabilitation program.

Study Design

Study Type:
Interventional
Actual Enrollment :
114 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Dual Treatment of Chronic Pain and Insomnia Within an Interdisciplinary Pain Rehabilitation Program
Actual Study Start Date :
Jun 6, 2019
Actual Primary Completion Date :
Jan 28, 2021
Actual Study Completion Date :
Apr 27, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: IPRP + CBT-I

Interdisciplinary Pain Rehabilitation Program + Cognitive Behavioral Therapy for Insomnia (IPRP + CBT-I)

Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I)
4-session CBT-I group in addition to IPRP

Behavioral: Interdisciplinary Pain Rehabilitation Program (IPRP)
10-week IPRP usual care

Active Comparator: IPRP-UC

Interdisciplinary Pain Rehabilitation Program Usual Care (IPRP-UC)

Behavioral: Interdisciplinary Pain Rehabilitation Program (IPRP)
10-week IPRP usual care

Outcome Measures

Primary Outcome Measures

  1. Insomnia severity [pre- and post-CBT-I intervention (group intervention weeks 1 and 4); pre- and post-IPRP intervention (IPRP weeks 0 and 10)]

    Insomnia Severity Index (ISI), a 7-item self-report measure was administered to assess insomnia symptoms at up to 4 time points: 1) IPRP admission (both groups), 2) IPRP discharge (10 weeks later; both groups); 3) CBT-I intervention week 1 (IPRP+CBT-I group only) and CBT-I intervention week 4 (IPRP+CBT-I group only)

Secondary Outcome Measures

  1. Pain severity [pre- and post-IPRP intervention (weeks 0 and 10)]

    Numeric pain scale (0-10 rating) for the time period of the past month was used to assess self-reported pain intensity

  2. Pain interference [pre- and post-IPRP intervention (weeks 0 and 10)]

    Patient Reported Outcomes Measurement Information System (PROMIS)-Pain Interference 8a was administered to assess self-reported pain-related life interference

  3. Depressed mood [pre- and post-IPRP intervention (weeks 0 and 10)]

    Patient Reported Outcomes Measurement Information System (PROMIS)-Depression 8a was used to assess self-reported depressed mood at the beginning and end of IPRP participation

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • enrolled in the IPRP

  • has chronic pain

  • Insomnia Severity Index (ISI) score of 8 or greater

  • English-speaking

  • able to provide informed consent

  • 18 years of age or older

Exclusion Criteria:
  • non-English-speaking

  • unable to provide informed consent

  • less than 18 years of age

  • ISI score less than 8

  • not concurrently enrolled in the IPRP

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mary Free Bed Rehabilitation Hospital Grand Rapids Michigan United States 49503

Sponsors and Collaborators

  • Mary Free Bed Rehabilitation Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Julia Craner Cooper, Psychologist, Mary Free Bed Rehabilitation Hospital
ClinicalTrials.gov Identifier:
NCT05033418
Other Study ID Numbers:
  • 2019.10
First Posted:
Sep 2, 2021
Last Update Posted:
Sep 2, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 2, 2021